Overview
A bleeding disorder refers to a condition, in which normal clotting function of the blood is adversely affected. Generally, on the injury site, the blood starts to clot, in order to prevent major blood loss. However, in certain situations blood clotting is prevented that can result in the prolonged bleeding. Furthermore, bleeding disorder can cause abnormal bleeding on both inside and outside of the body. In some cases, the amount of blood lost can be significant, while in other cases, it can cause bleeding to follow under the skin or in brain.
Normal blood clotting is comprised of different blood components namely platelets, along with 20 different plasma proteins. These are also referred to as coagulation factors that interact with other chemicals to forma substance known as fibrin that stops bleeding. However, certain complications can occur when some of these factors are low or missing in body. Bleeding problems can range from mild to severe. Some bleeding disorders are present at time of birth and some are passed through families (inherited).
Get Sample Report with Latest Covid19 Impact Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/527
According to American Society of Hematology, in 2016, around 20,000 people in the U.S. suffer from hemophilia, a condition that is predominantly observed in males. Hemophilia is the most well-known inherited bleeding disorder, although it is rather rare. On the other hand, many people are affected by von Willebrand disease, the most common inherited bleeding disorder in the U.S. caused by clotting proteins. This disease can affect both males and females and is found in nearly 1% of the U.S. population. And according to the Centers for Disease Control and Prevention (CDC) statistics, in the U.S. around 400 newborns suffer from hemophilia every year.
Rapid launch of generic products is expected to drive growth of the global bleeding disorders treatment market during the forecast period.
Rising public awareness, presence of large consumer base, favorable compensation policies, and available treatment options is expected to propel the global bleeding disorders treatment market growth over the forecast period. With patent expiry of existing brands, manufacturers have opportunities to launch generic products.
The global bleeding disorder market is mostly focused towards western countries of North America and Europe, owing to the high price of branded drugs. Low cost drugs will help in market penetration in under developed and developing countries, where patients cannot afford high cost of medical treatment. Hence, availability of cheap generic drugs will boost market growth in the countries of Middle East and Africa, Asia-Pacific (APAC), and Latin America.
Regional Insights
Among regions, North America is expected to account for the largest share in the global bleeding disorders treatment market over the forecast period. Furthermore, Asia Pacific is expected to exhibit the highest growth rate, owing to rising awareness regarding bleeding disorders in emerging economies such as China and India.
Technological developments will expand the boundaries of the market by adding new products such as Shire launched Vonvendi in the U.S. (In 2016), bringing the first recombinant von Willebrand factor treatment to market eight months after winning approval from the Food and Drug Administration(FDA). Key players operating in the global bleeding disorders treatment market are Bayer Healthcare, Biogen Idec, Novo Nordisk, Xenetic Biosciences, Shire, Sanofi, Cangene Corporation, CSL Behring, Alnylam Pharmaceuticals, Pfizer, Inc., Novo Nordisk, Amgen, Inc., Janssen Pharmaceuticals, and Octapharma.
Key Developments:
-
In February 2020, Novo Nordisk A/S launched Esperoct, an anti-hemophilic factor in U.S. for the treatment of adults and children with hemophilia A i.e., to reduce as well as control the bleeding episodes even during surgery.
-
In December 2019, Johnson and Johnson in collaboration with Spanish multinational, Grifols, produced Vistaseal biological sealant, which is a blood stopping protein spray and is designed to quickly seal and control bleeding during complicated surgeries where suturing, ligature or cauterization cannot be applied. The spray consist of two clotting, human fibrinogen and thrombin, which helps in the sealing of the wound.
-
In 2018, on the occasion of 70th anniversary of National Hemophilia Foundation (NHF), a Red Tie Campaign was launched in order to create awareness about the bleeding disorders. The main aim of the campaign was to increase the accessibility of the quality healthcare to the patient suffering from bleeding disorders by providing them health insurance with life time benefits.
-
In 2018, European Association for Hemophilia and Allied Disorders formed a working group on women and bleeding disorders after receiving the approval for the proposal. The aim of the working group is to educate the healthcare providers and understand the needs of the women with bleeding disorders.
-
In 2017, LFB Biopharmaceuticals launched FibCLOT, the human fibrinogen concentrate. FibCLOT is effective in patients with congenital hypo- or afibrinogenaemia and who have high tendency to bleed.
-
In 2017, Pfizer launched Hemocraft, a modification of the video game Minecraft, especially for children who are 8-16 years old. The game educates the children about the importance of integrating treatment in their daily lives.
-
In 2017, another modification by Pfizer involves the development of HemMobile Striiv Wearable wrist band, for the patients suffering from hemophilia. The device helps to track daily activity levels and also monitors heart rate. The device integrates with the Pfizer’s existing HemMobile app, which helps people to monitor their bleeding episodes.
-
In June 2016, a scientist working at Kingston Health Sciences Center (KGHRI) launched a website “Let’s Talk Period”, where the women need fill the “self- administered bleeding assessment” (Self – BAT) form in order to diagnose whether they are suffering from bleeding disorders or not. The website also directs the women to the referral centers where they can consult with the respective doctors for the effective treatment.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/527
Bleeding Disorders Treatment Market Taxonomy
By Type of Disorder,
-
Hemophilia A
-
Hemophilia B
-
von Willebrand Disease (vWD)
By Drug Class
-
Plasma Derived Coagulation Factor Concentrates
-
Recombinant Coagulation Factor Concentrate
-
Desmopressin
-
Antifibrinolytics
-
Fibrin sealants
-
Others
By Region
-
North America
-
Latin America
-
Europe
-
Asia Pacific
-
Middle East
-
Africa
Purchase This Premium Report To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/527
Table of Content
Global Bleeding Disorders Treatment Market Research Report
Section 1: Global Bleeding Disorders Treatment Industry Overview
Section 2: Global Economic Impact on Bleeding Disorders Treatment Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Bleeding Disorders Treatment Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Bleeding Disorders Treatment Market Forecast
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837